Acurx Pharmaceuticals’ (ACXP) Buy Rating Reiterated at HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold”.

Acurx Pharmaceuticals Stock Performance

ACXP stock traded up $0.01 during mid-day trading on Tuesday, reaching $1.28. 26,313 shares of the stock traded hands, compared to its average volume of 1,090,534. The business has a 50-day moving average price of $1.41 and a two-hundred day moving average price of $1.98. The stock has a market capitalization of $7.12 million, a PE ratio of -0.48 and a beta of -2.05. Acurx Pharmaceuticals has a one year low of $1.23 and a one year high of $8.34.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.15). On average, equities analysts expect that Acurx Pharmaceuticals will post -2 earnings per share for the current fiscal year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.